EIKN (EIKN) Competitors

$10.28 +0.01 (+0.10%)

Closing price 04:00 PM Eastern

Extended Trading

$10.30 +0.03 (+0.24%)

As of 04:10 PM Eastern

EIKN vs. AAPG, BHC, STOK, OCUL, and MESO

Should you be buying EIKN stock or one of its competitors? The main competitors of EIKN include Ascentage Pharma Group International (AAPG), Bausch Health Cos (BHC), Stoke Therapeutics (STOK), Ocular Therapeutix (OCUL), and Mesoblast (MESO). These companies are all part of the "pharmaceutical products" industry.

How does EIKN compare to Ascentage Pharma Group International?

EIKN (NASDAQ:EIKN) and Ascentage Pharma Group International (NASDAQ:AAPG) are both pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.

: Company Net Margins Return on Equity Return on Assets
EIKN N/A N/A N/A
Ascentage Pharma Group International N/A N/A N/A
: EIKN presently has a consensus price target of $25.60, suggesting a potential upside of 149.03%. Ascentage Pharma Group International has a consensus price target of $46.67, suggesting a potential upside of 111.83%. Given EIKN's higher probable upside, analysts clearly believe EIKN is more favorable than Ascentage Pharma Group International.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
EIKN
1 Sell rating(s)
1 Hold rating(s)

5 Buy rating(s)

0 Strong Buy rating(s)
2.57
Ascentage Pharma Group International
0 Sell rating(s)

0 Hold rating(s)

6 Buy rating(s)

2 Strong Buy rating(s)
3.25
: In the previous week, Ascentage Pharma Group International had 1 more articles in the media than EIKN. MarketBeat recorded 1 mentions for Ascentage Pharma Group International and 0 mentions for EIKN. Ascentage Pharma Group International's average media sentiment score of 1.16 beat EIKN's score of 0.00 indicating that Ascentage Pharma Group International is being referred to more favorably in the news media.
Company Overall Sentiment
EIKN Neutral
Ascentage Pharma Group International Positive
: EIKN has higher earnings, but lower revenue than Ascentage Pharma Group International.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
EIKN N/A N/A N/A N/A N/A
Ascentage Pharma Group International $82.10M 25.04 -$177.71M N/A N/A

Company	Net Margins	Return on Equity	Return on Assets
EIKN	N/A	N/A	N/A
Ascentage Pharma Group International	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
EIKN	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Ascentage Pharma Group International	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.25

Company	Overall Sentiment
EIKN	Neutral
Ascentage Pharma Group International	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
EIKN	N/A	N/A	N/A	N/A	N/A
Ascentage Pharma Group International	$82.10M	25.04	-$177.71M	N/A	N/A

Summary

Ascentage Pharma Group International beats EIKN on 6 of the 7 factors compared between the two stocks.

How does EIKN compare to Bausch Health Cos?

Bausch Health Cos (NYSE:BHC) and EIKN (NASDAQ:EIKN) are both pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, media sentiment, valuation, risk, dividends and analyst recommendations.

: EIKN has a net margin of 0.00% compared to Bausch Health Cos' net margin of -11.47%. Bausch Health Cos' return on equity of 503.18% beat EIKN's return on equity.
Company Net Margins Return on Equity Return on Assets
Bausch Health Cos -11.47% 503.18% 5.50%
EIKN N/A N/A N/A
: Bausch Health Cos currently has a consensus price target of $8.00, suggesting a potential upside of 41.72%. EIKN has a consensus price target of $25.60, suggesting a potential upside of 149.03%. Given EIKN's stronger consensus rating and higher possible upside, analysts plainly believe EIKN is more favorable than Bausch Health Cos.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bausch Health Cos
1 Sell rating(s)
4 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.80
EIKN
1 Sell rating(s)

1 Hold rating(s)

5 Buy rating(s)

0 Strong Buy rating(s)
2.57
: In the previous week, Bausch Health Cos had 17 more articles in the media than EIKN. MarketBeat recorded 17 mentions for Bausch Health Cos and 0 mentions for EIKN. Bausch Health Cos' average media sentiment score of 0.27 beat EIKN's score of 0.00 indicating that Bausch Health Cos is being referred to more favorably in the media.
Company Overall Sentiment
Bausch Health Cos Neutral
EIKN Neutral
: 78.7% of Bausch Health Cos shares are owned by institutional investors. 20.7% of Bausch Health Cos shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
: Bausch Health Cos has higher revenue and earnings than EIKN.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Bausch Health Cos $10.53B 0.20 $157M -$3.24 N/A
EIKN N/A N/A N/A N/A N/A

Company	Net Margins	Return on Equity	Return on Assets
Bausch Health Cos	-11.47%	503.18%	5.50%
EIKN	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch Health Cos	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
EIKN	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Company	Overall Sentiment
Bausch Health Cos	Neutral
EIKN	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch Health Cos	$10.53B	0.20	$157M	-$3.24	N/A
EIKN	N/A	N/A	N/A	N/A	N/A

Summary

Bausch Health Cos beats EIKN on 7 of the 11 factors compared between the two stocks.

How does EIKN compare to Stoke Therapeutics?

Stoke Therapeutics (NASDAQ:STOK) and EIKN (NASDAQ:EIKN) are both pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, media sentiment, valuation, risk, dividends and analyst recommendations.

: EIKN has a net margin of 0.00% compared to Stoke Therapeutics' net margin of -3.73%. EIKN's return on equity of 0.00% beat Stoke Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Stoke Therapeutics -3.73% -2.05% -1.75%
EIKN N/A N/A N/A
: Stoke Therapeutics currently has a consensus price target of $41.83, suggesting a potential upside of 26.92%. EIKN has a consensus price target of $25.60, suggesting a potential upside of 149.03%. Given EIKN's higher possible upside, analysts plainly believe EIKN is more favorable than Stoke Therapeutics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Stoke Therapeutics
0 Sell rating(s)
2 Hold rating(s)

9 Buy rating(s)

1 Strong Buy rating(s)
2.92
EIKN
1 Sell rating(s)

1 Hold rating(s)

5 Buy rating(s)

0 Strong Buy rating(s)
2.57
: In the previous week, Stoke Therapeutics had 4 more articles in the media than EIKN. MarketBeat recorded 4 mentions for Stoke Therapeutics and 0 mentions for EIKN. Stoke Therapeutics' average media sentiment score of 0.83 beat EIKN's score of 0.00 indicating that Stoke Therapeutics is being referred to more favorably in the media.
Company Overall Sentiment
Stoke Therapeutics Positive
EIKN Neutral
: EIKN has lower revenue, but higher earnings than Stoke Therapeutics.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Stoke Therapeutics $184.42M 11.13 -$6.89M -$0.12 N/A
EIKN N/A N/A N/A N/A N/A

Company	Net Margins	Return on Equity	Return on Assets
Stoke Therapeutics	-3.73%	-2.05%	-1.75%
EIKN	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stoke Therapeutics	0 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.92
EIKN	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Company	Overall Sentiment
Stoke Therapeutics	Positive
EIKN	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stoke Therapeutics	$184.42M	11.13	-$6.89M	-$0.12	N/A
EIKN	N/A	N/A	N/A	N/A	N/A

Summary

Stoke Therapeutics beats EIKN on 6 of the 10 factors compared between the two stocks.

How does EIKN compare to Ocular Therapeutix?

Ocular Therapeutix (NASDAQ:OCUL) and EIKN (NASDAQ:EIKN) are both pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their risk, media sentiment, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.

: In the previous week, Ocular Therapeutix had 14 more articles in the media than EIKN. MarketBeat recorded 14 mentions for Ocular Therapeutix and 0 mentions for EIKN. Ocular Therapeutix's average media sentiment score of 0.47 beat EIKN's score of 0.00 indicating that Ocular Therapeutix is being referred to more favorably in the media.
Company Overall Sentiment
Ocular Therapeutix Neutral
EIKN Neutral
: EIKN has lower revenue, but higher earnings than Ocular Therapeutix.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Ocular Therapeutix $51.95M 40.69 -$265.94M -$1.44 N/A
EIKN N/A N/A N/A N/A N/A
: Ocular Therapeutix currently has a consensus price target of $23.78, suggesting a potential upside of 144.88%. EIKN has a consensus price target of $25.60, suggesting a potential upside of 149.03%. Given EIKN's higher probable upside, analysts clearly believe EIKN is more favorable than Ocular Therapeutix.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ocular Therapeutix
1 Sell rating(s)
1 Hold rating(s)

12 Buy rating(s)

0 Strong Buy rating(s)
2.79
EIKN
1 Sell rating(s)

1 Hold rating(s)

5 Buy rating(s)

0 Strong Buy rating(s)
2.57
: 59.2% of Ocular Therapeutix shares are held by institutional investors. 2.3% of Ocular Therapeutix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
: EIKN has a net margin of 0.00% compared to Ocular Therapeutix's net margin of -511.90%. EIKN's return on equity of 0.00% beat Ocular Therapeutix's return on equity.
Company Net Margins Return on Equity Return on Assets
Ocular Therapeutix -511.90% -70.68% -50.53%
EIKN N/A N/A N/A

Company	Overall Sentiment
Ocular Therapeutix	Neutral
EIKN	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocular Therapeutix	$51.95M	40.69	-$265.94M	-$1.44	N/A
EIKN	N/A	N/A	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocular Therapeutix	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
EIKN	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Company	Net Margins	Return on Equity	Return on Assets
Ocular Therapeutix	-511.90%	-70.68%	-50.53%
EIKN	N/A	N/A	N/A

Summary

Ocular Therapeutix beats EIKN on 7 of the 11 factors compared between the two stocks.

How does EIKN compare to Mesoblast?

EIKN (NASDAQ:EIKN) and Mesoblast (NASDAQ:MESO) are both pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation, media sentiment and analyst recommendations.

: In the previous week, Mesoblast had 10 more articles in the media than EIKN. MarketBeat recorded 10 mentions for Mesoblast and 0 mentions for EIKN. EIKN's average media sentiment score of 0.00 beat Mesoblast's score of -0.20 indicating that EIKN is being referred to more favorably in the media.
Company Overall Sentiment
EIKN Neutral
Mesoblast Neutral
: EIKN has higher earnings, but lower revenue than Mesoblast.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
EIKN N/A N/A N/A N/A N/A
Mesoblast $65.38M 31.26 -$102.14M -$0.54 N/A
: EIKN currently has a consensus price target of $25.60, suggesting a potential upside of 149.03%. Given EIKN's stronger consensus rating and higher probable upside, equities research analysts clearly believe EIKN is more favorable than Mesoblast.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
EIKN
1 Sell rating(s)
1 Hold rating(s)

5 Buy rating(s)

0 Strong Buy rating(s)
2.57
Mesoblast
1 Sell rating(s)

1 Hold rating(s)

0 Buy rating(s)

1 Strong Buy rating(s)
2.33
: 1.4% of Mesoblast shares are owned by institutional investors. 18.8% of Mesoblast shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
: Company Net Margins Return on Equity Return on Assets
EIKN N/A N/A N/A
Mesoblast N/A N/A N/A

Company	Overall Sentiment
EIKN	Neutral
Mesoblast	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
EIKN	N/A	N/A	N/A	N/A	N/A
Mesoblast	$65.38M	31.26	-$102.14M	-$0.54	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
EIKN	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Mesoblast	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

Company	Net Margins	Return on Equity	Return on Assets
EIKN	N/A	N/A	N/A
Mesoblast	N/A	N/A	N/A

Summary

Mesoblast beats EIKN on 5 of the 9 factors compared between the two stocks.

Get EIKN News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EIKN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EIKN vs. The Competition

Export

Metric	EIKN	Biological Products, Except Diagnostic Substances Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$556.55M	$362.87M	$4.21B	$11.87B
Dividend Yield	N/A	N/A	5.61%	5.21%
P/E Ratio	N/A	N/A	23.40	28.47
Price / Sales	N/A	372.54	186.85	60.94
Price / Cash	N/A	N/A	52.82	36.52
Price / Book	N/A	2.81	38.31	6.67
Net Income	N/A	-$81.71M	$114.66M	$332.53M
7 Day Performance	20.09%	6.50%	1.23%	2.01%
1 Month Performance	3.84%	5.53%	5.54%	9.20%
1 Year Performance	N/A	N/A	18.68%	39.59%

EIKN Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EIKN EIKN	N/A	$10.28 +0.1%	$25.60 +149.0%	N/A	$556.55M	N/A	N/A	384
AAPG Ascentage Pharma Group International	4.4239 of 5 stars	$22.02 -5.7%	$46.67 +111.9%	N/A	$2.18B	$82.10M	N/A	600	Positive News
BHC Bausch Health Cos	2.0562 of 5 stars	$5.53 -2.2%	$8.00 +44.8%	N/A	$2.11B	$10.27B	N/A	20,300	Earnings Report Analyst Downgrade
STOK Stoke Therapeutics	2.8439 of 5 stars	$34.18 +3.3%	$41.83 +22.4%	N/A	$2.06B	$184.42M	N/A	100	Upcoming Earnings
OCUL Ocular Therapeutix	3.5259 of 5 stars	$9.77 +3.6%	$23.78 +143.4%	N/A	$2.05B	$51.95M	N/A	230	Trending News Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EIKN) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

EIKN (EIKN) Competitors

EIKN vs. AAPG, BHC, STOK, OCUL, and MESO

How does EIKN compare to Ascentage Pharma Group International?

Summary

How does EIKN compare to Bausch Health Cos?

Summary

How does EIKN compare to Stoke Therapeutics?

Summary

How does EIKN compare to Ocular Therapeutix?

Summary

How does EIKN compare to Mesoblast?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EIKN vs. The Competition

EIKN Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

EIKN (EIKN) Competitors

EIKN vs. AAPG, BHC, STOK, OCUL, and MESO

How does EIKN compare to Ascentage Pharma Group International?

Summary

How does EIKN compare to Bausch Health Cos?

Summary

How does EIKN compare to Stoke Therapeutics?

Summary

How does EIKN compare to Ocular Therapeutix?

Summary

How does EIKN compare to Mesoblast?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EIKN vs. The Competition

EIKN Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools